Skip to main content

15-04-2010 | Cardiometabolic | Article

Adiponectin linked with cardiometabolic risk in West Africans


Free abstract

MedWire News: Circulating levels of adiponectin are associated with measures of obesity, lipids, and insulin resistance in West African individuals, study findings reveal.

The findings mirror observations in Western populations and add to our understanding of adiponectin’s functions and its potential for therapeutic manipulation, say Charles Rotimi (National Human Genome Research Institute, Bethesda, Maryland, USA) and fellow researchers.

The study was a cross-sectional analysis of adiponectin in relation to demographic, lipid, and metabolic factors among 690 men and women living in West Africa. The participants were acting as healthy controls in the Africa-American Diabetes Mellitus study.

As reported in the Journal of Clinical Endocrinology and Metabolism, mean adiponectin levels were 5225.1 ng/ml in men and 6942.2 ng/ml in women, a statistically significant difference.

In both men and women, log-transformed adiponectin levels positively correlated with age and negatively correlated with body mass index and waist circumference.

Adiponectin also negatively correlated with percent fat mass in women, but not in men. Further analysis revealed that body mass index was a stronger determinant of log-adiponectin levels than were waist circumference and percent fat mass.

With regard to cardiometabolic factors, log-transformed adiponectin levels positively correlated with total cholesterol and high-density lipoprotein (HDL) cholesterol and negatively correlated with triglycerides and insulin resistance.

Rotimi et al say that increasing evidence points to a protective role for adiponectin in obesity-related complications, including ameliorating insulin resistance, diabetes, and atherosclerosis.

Furthermore, adiponectin levels have been positively associated with HDL cholesterol and negatively associated with low-density lipoprotein cholesterol and triglycerides, suggesting a role not only in obesity but also in dyslipidemia.

“Advances in the understanding of the role of adiponectin and its potential for therapeutic intervention are promising and particularly important in light of the epidemic of obesity,” they conclude.

“This first large-scale epidemiologic investigation of the relationship between adiponectin and measures of obesity, serum lipids, and insulin resistance in West Africans provides several interesting findings worthy of further research.”

MedWire ( is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Joanna Lyford